Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome
Open accessAbstract
Silencing the gene FMR1 in fragile X syndrome (FXS) with consequent loss of its protein product, FMRP, results in intellectual disability, hyperactivity, anxiety, seizure disorders, and autism-like behavior. In a mouse model (Fmr1 knockout (KO)) of FXS, a deficit in performance on the passive avoidance test of learning and memory is a robust phenotype. We report that drugs acting on the endocannabinoid (eCB) system can improve performance on this test. We present three lines of evidence: (1) Propofol (reported to inhibit fatty acid amide hydrolase (FAAH) activity) administered 30 min after training on the passive avoidance test improved performance in Fmr1 KO mice but had no effect on wild type (WT). FAAH catalyzes the metabolism of the eCB, anandamide, so its inhibition should result in increased anandamide levels. (2) The effect of propofol was blocked by prior administration of the cannabinoid receptor 1 antagonist AM-251. (3) Treatment with the FAAH inhibitor, URB-597, administered 30 min after training on the passive avoidance test also improved performance in Fmr1 KO mice but had no effect on WT. Our results indicate that the eCB system is involved in FXS and suggest that the eCB system is a promising target for treatment of FXS.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Animal models of both FXS and ASD have shown benefits when treated with CBD.
“Animal models of both FXS and ASD have shown benefits when treated with CBD [121, 122].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · see citing works
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529 · see citing works
Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery
Trapani, G., Altomare, C., Sanna, E., Biggio, G., & Liso, G. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003375335 · Cited by 423 · see citing works
Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome
Jung, K., Sepers, M. D., Henstridge, C. M., Lassalle, O., Neuhofer, D. N., Martin, H. G. S., Ginger, M. R., Frick, A., DiPatrizio, N. V., Mackie, K., et al. (2012) · Nature Communications · doi:10.1038/ncomms2045 · Cited by 282 · see citing works
Qin, M., Kang, J., Burlin, T. V., Jiang, C., & Smith, C. B. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0093-05.2005 · Cited by 263 · see citing works
Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety
Gray, J. M., Vecchiarelli, H. A., Morena, M., Lee, T. T. Y., Hermanson, D. J., Kim, A. B., McLaughlin, R. J., Hassan, K. I., Kühne, C., Wotjak, C. T., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2737-14.2015 · Cited by 246 · see citing works
Ronesi, J. A., & Huber, K. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5019-07.2008 · Cited by 244 · see citing works
Targeting the endocannabinoid system in the treatment of fragile X syndrome
Busquets-Garcia, A., Gomis-González, M., Guegan, T., Agustín-Pavón, C., Pastor, A., Mato, S., Pérez-Samartín, A., Matute, C., de la Torre, R., Dierssen, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3127 · Cited by 241 · see citing works
Hill, M. N., Kumar, S. A., Filipski, S. B., Iverson, M., Stuhr, K. L., Keith, J. M., Cravatt, B. F., Hillard, C. J., Chattarji, S., & McEwen, B. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.90 · Cited by 222 · see citing works
Mines, M. A., Yuskaitis, C. J., King, M. K., Beurel, E., & Jope, R. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009706 · Cited by 208 · see citing works
Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome
Liu, Z., Chuang, D., & Smith, C. B. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000520 · Cited by 159 · see citing works
Patel, S., Wohlfeil, E. R., Rademacher, D. J., Carrier, E. J., Perry, L. J., Kundu, A., Falck, J. R., Nithipatikom, K., Campbell, W. B., & Hillard, C. J. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705334 · Cited by 148 · see citing works
Mazzola, C., Medalie, J., Scherma, M., Panlilio, L. V., Solinas, M., Tanda, G., Drago, F., Cadet, J. L., Goldberg, S. R., & Yaşar, S. (2009) · Learning & Memory · doi:10.1101/lm.1145209 · Cited by 130 · see citing works
Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background
Ding, Q., Sethna, F., & Wang, H. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.046 · Cited by 121 · see citing works
Abnormal mGlu 5 Receptor/Endocannabinoid Coupling in Mice Lacking FMRP and BC1 RNA
Maccarrone, M., Rossi, S., Bari, M., Chiara, V. D., Rapino, C., Musella, A., Bernardi, G., Bagni, C., & Centonze, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.19 · Cited by 119 · see citing works
Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome.
Liu, Z.-H., & Smith, C. B. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.02.066 · Cited by 112 · see citing works
Self-citationEnhanced Endocannabinoid Signaling Elevates Neuronal Excitability in Fragile X Syndrome
Zhang, L., & Alger, B. E. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0795-10.2010 · Cited by 104 · see citing works
Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation
Qin, M., Kang, J. Y., & Smith, C. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242377399 · Cited by 93 · see citing works
Propofol Enhances Memory Formation via an Interaction with the Endocannabinoid System
Hauer, D., Ratano, P., Morena, M., Scaccianoce, S., Briegel, I., Palmery, M., Cuomo, V., Roozendaal, B., Schelling, G., & Campolongo, P. (2011) · Anesthesiology · doi:10.1097/aln.0b013e31821c120e · Cited by 68 · see citing works
Qin, M., Schmidt, K., Zametkin, A. J., Bishu, S., Horowitz, L. M., Burlin, T. V., Xia, Z., Huang, T., Quezado, Z., & Smith, C. B. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.205 · Cited by 58 · see citing works
Tang, A.-H., & Alger, B. E. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4499-14.2015 · Cited by 39 · see citing works
Melis, M., Greco, B., & Tonini, R. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12501 · Cited by 30 · see citing works
Bishu, S., Schmidt, K., Burlin, T. V., Charming, M. A., Horowitz, L. M., Huang, T., Liu, Z.-H., Qin, M., Vuong, B.-K., Unterman, A. J., et al. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.7 · Cited by 28 · see citing works
The inhibitory avoidance test optimized for discovery of cognitive enhancers
Detrait, E., Hanon, É., Dardenne, B., & Lamberty, Y. (2009) · Behavior Research Methods · doi:10.3758/brm.41.3.805 · Cited by 21 · see citing works
Fmr1 deletion enhances and ultimately desensitizes CB1 signaling in autaptic hippocampal neurons
Straiker, A. J., Min, K., & Mackie, K. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.002 · Cited by 21 · see citing works
Brief Report: Altered Social Behavior in Isolation-Reared Fmr1 Knockout Mice
Heitzer, A. M., Roth, A. K., Nawrocki, L., Wrenn, C. C., & Valdovinos, M. G. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1670-1 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233 · see citing works
Fragile X targeted pharmacotherapy: lessons learned and future directions
Erickson, C. A., Davenport, M. H., Schaefer, T. L., Wink, L. K., Pedapati, E. V., Sweeney, J. A., Fitzpatrick, S. E., Brown, W. T., Budimirovic, D. B., Hagerman, R. J., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9186-9 · Cited by 153 · see citing works
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models
Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091916 · Cited by 127 · see citing works
Fleury-Teixeira, P., Caixeta, F. V., da Silva, L. C. R., Brasil-Neto, J. P., & Malcher‐Lopes, R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01145 · Cited by 125 · see citing works
An endocannabinoid-regulated basolateral amygdala–nucleus accumbens circuit modulates sociability
Folkes, O. M., Báldi, R., Kondev, V., Marcus, D. J., Hartley, N. D., Turner, B. D., Ayers, J. K., Baechle, J. J., Misra, M. P., Altemus, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131752 · Cited by 119 · see citing works
Heussler, H., Cohen, J., Silove, N., Tich, N., Bonn-Miller, M. O., Du, W., O’Neill, C., & Sebree, T. (2019) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-019-9277-x · Cited by 106 · see citing works
Zamberletti, E., Gabaglio, M., Woolley-Roberts, M., Bingham, S., Rubino, T., & Parolaro, D. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00367 · Cited by 95 · see citing works
Kerr, D. M., Aoife, G., & Roche, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.033 · Cited by 86 · see citing works
Doenni, V. M., Gray, J. M., Song, C. M., Patel, S., Hill, M. N., & Pittman, Q. J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.07.152 · Cited by 80 · see citing works
Endocannabinoid signaling in social functioning: an RDoC perspective
Karhson, D. S., Hardan, A. Y., & Parker, K. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.169 · Cited by 62 · see citing works
Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism
Zieba, J., Sinclair, D., Sebree, T. B., Bonn‐Miller, M. O., Gutterman, D. L., Siegel, S. J., & Karl, T. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.05.002 · Cited by 60 · see citing works
FMR1 and Autism, an Intriguing Connection Revisited
Fyke, W., & Velinov, M. T. (2021) · Genes · doi:10.3390/genes12081218 · Cited by 59 · see citing works
Tartaglia, N. R., Bonn‐Miller, M. O., & Hagerman, R. J. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0053 · Cited by 57 · see citing works
Martella, G., Meringolo, M., Trobiani, L., Jaco, A. D., Pisani, A., & Bonsi, P. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13705 · Cited by 56 · see citing works
Deficient Sleep in Mouse Models of Fragile X Syndrome
Saré, R. M., Harkless, L. H., Levine, M., Torossian, A., Sheeler, C. A., & Smith, C. B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00280 · Cited by 54 · see citing works
Kuo, H., & Liu, F. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00422 · Cited by 46 · see citing works
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi, J. F. C., Ferreira, F. R., Silva-Amaral, D., Lima, D. D. A., Hallak, J. E. C., Zuardi, A. W., Bel, E. A. D., Guimarães, F. S., Costa, K. C. M., Campos, A. C., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06196-4 · Cited by 52 · see citing works
Kat, R., Arroyo-Araujo, M., de Vries, R. B. M., Koopmans, M. A., de Boer, S. F., & Kas, M. J. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104722 · Cited by 42 · see citing works
Hill, M. N., Haney, M., Hillard, C. J., Karhson, D. S., & Vecchiarelli, H. A. (2023) · Psychological Medicine · doi:10.1017/s0033291723002465 · Cited by 39 · see citing works
Kruk-Słomka, M., Boguszewska‐Czubara, A., Słomka, T., Budzyńska, B., & Biała, G. (2015) · Neural Plasticity · doi:10.1155/2016/9815092 · Cited by 37 · see citing works
Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story
Carbone, E., Manduca, A., Cacchione, C., Vicari, S., & Trezza, V. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.009 · Cited by 37 · see citing works
Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
Lee, A. W., Ventola, P. E., Budimirovic, D. B., Berry‐Kravis, E., & Visootsak, J. (2018) · Brain Sciences · doi:10.3390/brainsci8120214 · Cited by 33 · see citing works
Autism-like behavior in the BTBR mouse model of autism is improved by propofol
Cai, Y., Wang, L. Y., Xiao, R., Li, X., He, X., Gao, J., Xu, H., & Fan, X. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.021 · Cited by 30 · see citing works
Modelling fragile X syndrome in the laboratory setting: A behavioral perspective
Melancia, F., & Trezza, V. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.04.042 · Cited by 29 · see citing works
Role of the endocannabinoid system in neurological disorders
Zou, M., Li, D., Li, L., Wu, L., & Sun, C. (2019) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2019.03.002 · Cited by 28 · see citing works
Loss, C. M., Teodoro, L., Rodrigues, G. D., Moreira, L. R., Peres, F. F., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Abílio, V. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.635763 · Cited by 27 · see citing works
Lipid-Based Molecules on Signaling Pathways in Autism Spectrum Disorder
Yui, K., Imataka, G., & Yoshihara, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179803 · Cited by 27 · see citing works
Schiavi, S., Manduca, A., Carbone, E., Buzzelli, V., Rava, A., Feo, A., Ascone, F., Morena, M., Campolongo, P., Hill, M. N., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01454-7 · Cited by 26 · see citing works
Behavioral Phenotype ofFmr1Knock-Out Mice during Active Phase in an Altered Light/Dark Cycle
Saré, R. M., Levine, M., & Smith, C. B. (2016) · eNeuro · doi:10.1523/eneuro.0035-16.2016 · Cited by 25 · see citing works
Pietropaolo, S., & Marsicano, G. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.031 · Cited by 23 · see citing works
Neuhofer, D. N., Lassalle, O., & Manzoni, O. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00398 · Cited by 23 · see citing works
The role of the endocannabinoid system in autism spectrum disorders: Evidence from mouse studies
Pietropaolo, S., Bellocchio, L., Bouzón‐Arnáiz, I., & Yee, B. K. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.04.016 · Cited by 23 · see citing works
Pirbhoy, P. S., Jonak, C. R., Syed, R., Argueta, D. A., Perez, P. A., Wiley, M. B., Hessamian, K., Lovelace, J. W., Razak, K. A., DiPatrizio, N. V., et al. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09394-x · Cited by 23 · see citing works
Contarini, G., Ferretti, V., & Papaleo, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00787 · Cited by 22 · see citing works
p21-activated kinase 1 restricts tonic endocannabinoid signaling in the hippocampus
Xia, S., Zhou, Z., Leung, C., Zhu, Y., Pan, X., Qi, J., Morena, M., Hill, M. N., Xie, W., & Jia, Z. (2016) · eLife · doi:10.7554/elife.14653 · Cited by 21 · see citing works
Autism and associated disorders: cannabis as a potential therapy
Babayeva, M., Assefa, H., Basu, P., & Loewy, Z. G. (2022) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1401001 · Cited by 21 · see citing works
Differential Adulthood Onset mGlu5Signaling Saves Prefrontal Function in the Fragile X Mouse
Martin, H. G. S., Lassalle, O., & Manzoni, O. J. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw328 · Cited by 20 · see citing works
A Spectrum of Solutions: Unveiling Non-Pharmacological Approaches to Manage Autism Spectrum Disorder
Mondal, A., Sharma, R., Abiha, U., Ahmad, F., Karan, A., Jayaraj, R. L., & Sundar, V. (2023) · Medicina · doi:10.3390/medicina59091584 · Cited by 17 · see citing works
Endocannabinoid System Unlocks the Puzzle of Autism Treatment via Microglia
Su, T., Yan, Y., Li, Q., Ye, J., & Pei, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.734837 · Cited by 14 · see citing works
New Myrtenal–Adamantane Conjugates Alleviate Alzheimer’s-Type Dementia in Rat Model
Dragomanova, S., Lazarova, M. I., Munkuev, A. A., Суслов, Е. В., Volcho, K. P., Salakhutdinov, N. F., Bibi, A., Reynisson, J., Tzvetanova, E., Alexandrova, A., et al. (2022) · Molecules · doi:10.3390/molecules27175456 · Cited by 13 · see citing works
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R. J., & Restrepo, B. (2024) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.24022006 · Cited by 15 · see citing works
Coccurello, R., Marrone, M. C., & Maccarrone, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869606 · Cited by 12 · see citing works
The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics
Ahmed, M., Boileau, I., Le Foll, B., Carvalho, A. F., & Kloiber, S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1926 · Cited by 11 · see citing works
Jana, A., Nath, A., Sen, P., Kundu, S., Alghamdi, B. S. A., Abujamel, T. S., Saboor, M., Chan, W., Alexiou, A. T., Papadakis, M., et al. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08781-6 · Cited by 11 · see citing works
Campanale, A., Siniscalco, D., & Marzo, V. D. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01145-7 · Cited by 11 · see citing works
CB1 receptor antagonism in capuchin monkeys alters social interaction and aversive memory extinction
Gonczarowska, N., Tomaz, C. A. B., Caixeta, F. V., Malcher‐Lopes, R., Barros, M., Nishijo, H., & Maior, R. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05305-0 · Cited by 10 · see citing works
Therapeutic potential of CBD in Autism Spectrum Disorder
Pedrazzi, J. F. C., Hassib, L., Ferreira, F. R., Hallak, J. E. C., Del-Bel, E., & Crippa, J. A. S. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.05.002 · Cited by 11 · see citing works
Drug Treatments for Neurodevelopmental Disorders: Targeting Signaling Pathways and Homeostasis
Kaufmann, W. E., Luu, S., & Budimirovic, D. B. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01394-3 · Cited by 8 · see citing works
Melatonin attenuates scopolamine‐induced cognitive dysfunction through SIRT1/IRE1α/XBP1 pathway
Liu, X., Huang, S., Zheng, J., Wan, C., Tian, H., Cai, Y., Wang, Q., & Zhang, S. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14891 · Cited by 7 · see citing works
Saré, R. M., Lemons, A. H. S., & Smith, C. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.811528 · Cited by 6 · see citing works
Daily oscillation of the excitation/inhibition ratio is disrupted in two mouse models of autism
Bridi, M., Luo, N., Kim, G., Menarchek, B. J., Lee, R. A., Rodríguez, B. A., Severín, D., Moreno, C., Contreras, A., Wesselborg, C., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111494 · Cited by 5 · see citing works
Jia, X., Gao, S., Liu, X., Feng, Z., Wang, X. X., Lan, K., Lu, Y., Han, L., Wei, Y. B., & Liu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02031-x · Cited by 4 · see citing works
Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
Telias, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191102165206 · Cited by 4 · see citing works
Endocannabinoid contributions to the perception of socially relevant, affective touch in humans
Jones, M. R., Haggarty, C. J., Petrie, G. N., Lunge, A. R., Morrison, I., Hill, M. N., Heilig, M. A., & Mayo, L. M. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02053-y · Cited by 3 · see citing works
Synaptic protein mutations in autism
Sauer, A. K., Walsh, J. A., Curran, D., Zohourian, N., Stanton, J. E., Zabetakis, I., Brown, J. A. L., & Grabrucker, A. M. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107365 · Cited by 3 · see citing works
Implication of the endocannabidiome and metabolic pathways in fragile X syndrome pathophysiology
Dionne, O., Abolghasemi, A., Corbin, F., & Çaku, A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115962 · Cited by 1 · see citing works
The endocannabinoid system in autism spectrum disorder
Costello, J. A., & Roche, M. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00018-9 · Cited by 1 · see citing works
Medical use of cannabidiol in fragile X syndrome
Johnson, D., & Hagerman, R. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90036-2.00029-6 · Cited by 1 · see citing works
Daily oscillation of the excitation/inhibition ratio is disrupted in two mouse models of autismPreprint
Bridi, M., Luo, N., Kim, G., O’Ferrall, C., Patel, R. V., Bertrand, S. J., Kannan, S., & Kirkwood, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.05.451213 · Cited by 1 · see citing works
El-Sukkari, D., Sharma, K., Fleiss, B., Braganza, D. L., Crichton, A. J., & Fahey, M. C. (2023) · medRxiv · doi:10.1101/2023.12.05.23299505 · Cited by 1 · see citing works
The Endocannabinoid System in Fragile X Syndrome
Martin, H. G. S., Neuhofer, D. N., & Manzoni, O. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00012-3
The effect of propofol on mental health in Saudi Arabia
Albanna, A. K., Alnefaie, Z. M., Shammari, A. M. A., Alsayedeash, F. H., Alalwei, R. H., Alturki, A. I., Aljohani, A. A., Alammari, S. B., & Alrufaydi, G. A. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20251418
Cannabidiol-Induced Recovery of Social Behaviour in Mouse Models of Syndromic AutismPreprint
Parkhill, M., Lewis, V., Baglot, S. L., Rodrigue, B., Hill, M. N., & Aguilar‐Valles, A. (2025) · Research Square · doi:10.21203/rs.3.rs-6683632/v1
Watt, G., & Karl, T. (2025) · Springer eBooks · doi:10.1007/978-3-031-87990-6_14
The endocannabinoid system in intellectual disability
Vázquez-Oliver, A., Reyes‐Ramírez, L. D. L., Galera-López, L., & Ozaita, A. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-13908-6.00022-0
Pirbhoy, P. S., Jonak, C. R., Syed, R., Argueta, D. A., Perez, P. A., Wiley, M. B., Hessamian, K., Lovelace, J. W., Razak, K. A., DiPatrizio, N. V., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16807858
- Authors
- Qin, M., Zeidler, Z., Moulton, K., Krych, L., Xia, Z., & Smith, C. B.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Smith, Carolyn B.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 291
- Pages
- 164-171
- ISSN
- 0166-4328 (ISSN-L)
- PMC
- PMC5003021
- OpenAlex
- W1674182966
- Cited by
- 69
- References
- 26
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 7 · 2023: 6 · 2022: 9 · 2021: 9 · 2020: 2 · 2019: 10 · 2018: 4 · 2017: 6 · 2016: 6 · 2015: 1
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Behavioural Brain Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- fragile X syndrome, endocannabinoid system, FMRP, Fmr1 knockout mice, passive avoidance, aversive memory, propofol, fatty acid amide hydrolase inhibition, anandamide, CB1 receptor, AM251, learning and memory impairment, therapeutic target
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Avoidance Learning, Benzamides, Carbamates, Disease Models, Animal, Enzyme Inhibitors, Fragile X Syndrome, Male, Memory, Mice, Inbred C57BL, Piperidines, Pyrazoles, Receptors, GABA-A, Social Behavior, Propofol, Mice, Knockout, Receptor, Cannabinoid, CB1, Fragile X Mental Retardation Protein, Fragile X Messenger Ribonucleoprotein 1, Polyunsaturated Alkamides, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
